Clinical Trials Logo

Filter by:
NCT ID: NCT01135225 Completed - Clinical trials for Coronary Artery Disease

Non-inferiority Trial to Assess the Safety and Performance of the Evolution Coronary Stent

Evolve
Start date: July 2010
Phase: N/A
Study type: Interventional

The purpose of the EVOLVE Trial is to assess the safety and performance of the everolimus-eluting Evolution stent for the treatment of a de novo atherosclerotic lesion of up to 28 mm in length in a native coronary artery 2.25 mm to 3.5 mm in diameter. The safety and performance of two different drug release rate formulations of the Evolution Stent will be compared to the commercially available PROMUS (TM) Element (TM) drug-eluting stent.

NCT ID: NCT01134055 Completed - Clinical trials for Macular Degeneration

Dose Ranging Study of Pazopanib to Treat Neovascular Age-Related Macular Degeneration

Start date: June 1, 2010
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the safety and efficacy of different dosage regimens of pazopanib eye drops for the treatment of neovascular age-related macular degeneration.

NCT ID: NCT01133782 Completed - Clinical trials for Acute Respiratory Tract Infection

Clinical Application of PCR-based Diagnosis of Community-onset Viral Respiratory Infections.

luftvagsPCR
Start date: October 2006
Phase: N/A
Study type: Interventional

Viral respiratory infections are common worldwide. It has been suggested that nucleic acid amplification tests, enabling a rapid etiologic diagnosis, may be useful in reducing antibiotic prescriptions rates. The objective of this study was to evaluate if access to a multiplex real-time PCR method would have an impact on antibiotic prescriptions for acute respiratory tract infections (ARTIs), in primary care. Adult patients with respiratory tract infections will be prospectively included. Nasopharyngeal and throat swabs will be analyzed with a multiplex real-time PCR method, targeting 13 viruses and two bacteria. Samples will be collected during the winter season (October-April). Patients will be open-label randomised to receive a rapid result (the following day) or a delayed result (after 10+/-2 days). The investigators are planning to include approximately 400 patients. Prescription of antibiotics will be measured at initial visit as well as at a follow-up visit 10+/-2 days later. Primary endpoint is antibiotic prescription in the acute phase (initial visit) and secondary endpoint antibiotic treatment (ongoing or initiated) at follow-up visit. The hypohesis is that access to a method with the ability of providing a rapid etiologic diagnosis of respiratory infections will affect the use of antibiotics in outpatient care of adult patients with ARTI.

NCT ID: NCT01132495 Completed - Clinical trials for Coronary Artery Disease

FAME II - Fractional Flow Reserve (FFR) Guided Percutaneous Coronary Intervention (PCI) Plus Optimal Medical Treatment (OMT) Verses OMT

Start date: May 2010
Phase: N/A
Study type: Interventional

The overall purpose of the FAME II trial is to compare the clinical outcomes, safety and cost-effectiveness of FFR-guided PCI plus optimal medical treatment (OMT) versus OMT alone in patients with stable coronary artery disease.

NCT ID: NCT01131910 Completed - Clinical trials for Rheumatoid Arthritis

TBE-vaccine to Patients With Rheumatoid Arthritis Who Are Using Immunosuppressive Drugs

Start date: May 2010
Phase: Phase 2
Study type: Interventional

The investigators intend to check whether the efficacy of a TBE-vaccine is substantially deteriorated in patients with rheumatoid arthritis who are treated with drugs which suppress the immune system. The investigators aim to detect a difference of at least 10 % compared to healthy individuals (historical controls) in protection when analysed with serology. If the investigators detect a difference, the investigators will continue to explore whether protection can be achieved by additional doses

NCT ID: NCT01131858 Completed - Clinical trials for Primary Immune Deficiency Disorder

Study of Vitamin D3 Substitution to Patients With Primary Immunodeficiency

VITAPID
Start date: March 2010
Phase: Phase 1/Phase 2
Study type: Interventional

Hypothesis: Cholecalciferol (vitamin D3) prevent respiratory tract infections in patients with primary immunodeficiency.

NCT ID: NCT01131624 Completed - Anaemia Clinical Trials

Comparative Efficacy and Safety of Intravenous Ferric Carboxymaltose (FCM) Versus Oral Iron for Iron Deficiency Anaemia in Pregnant Women

ASAP
Start date: May 2010
Phase: Phase 3
Study type: Interventional

The purpose of this study is to look at how well Ferric Carboxymaltose, an intravenous iron therapy (iron that is infused directly into your body through a vein), compares with ferrous sulphate capsules taken by mouth in the treatment of iron deficiency anaemia during pregnancy.

NCT ID: NCT01128595 Completed - Asthma Clinical Trials

Randomised Study Comparing the Effects of Inhaled FF/GW642444M Combination, FF and GW642444M on an Allergen Induced Asthmatic Response

Start date: May 2010
Phase: Phase 2
Study type: Interventional

We propose to use an inhaled allergen challenge model to explore the individual contributions of the components of a novel long-acting beta agonist/ inhaled corticosteroid combination product and its components on protection from allergic triggers in asthma

NCT ID: NCT01127828 Completed - Quality of Life Clinical Trials

Effects of Cultura Yoghurt in Irritable Bowel Syndrome (IBS) Patients on Intestinal and Immunological Changes

Start date: September 2005
Phase: N/A
Study type: Interventional

To determine the effect of cultura probiotic yoghurt on number of responders to treatment during 8 weeks of treatment in comparison to placebo. To determine the effect of cultura yoghurt on change in total score of (IBS) irritable bowel syndrome severity index during 8 weeks of treatment in comparison to placebo in IBS out patients.

NCT ID: NCT01127750 Completed - Clinical trials for Relapsing Multiple Sclerosis

Tolerability and Safety and Health Outcomes in Relapsing Multiple Sclerosis (MS) Patients

Start date: May 2010
Phase: Phase 3
Study type: Interventional

This study will assess tolerability and safety and health outcomes in relapsing MS patients taking FTY720.